CoChat
Sign Up
Cited by 102

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Peptides as drug delivery vehicles across biological barriers

Ghosh, Debadyuti, Peng, Xiujuan, Leal, Jasmim, Mohanty, Rashmi P.·2018·Journal of Pharmaceutical Investigation
DOI 10.1007/s40005-017-0374-0PMC PMC6023411
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40005-017-0374-0

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 187

  1. AC’t Hoen PAC, Jirka SMG, Ten Broeke BR et al (2012) Phage display screening without repetitious selection rounds. Anal Biochem 421:622–631. https://doi.org/10.1016/j.ab.2011.11.005 · DOI
  2. Agarwal V (2001) Current status of the oral delivery of insulin. Pharm Technol 25:76–90
  3. Agemy L (2011) Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Nat Acad Sci 108:17450–17455. https://doi.org/10.1073/pnas.1114518108 · DOI
  4. Aguirre TAS, Teijeiro-Osorio D, Rosa M et al (2016) Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev 106:223–241. https://doi.org/10.1016/j.addr.2016.02.004 · DOI
  5. Akerman ME, Chan WCW, Laakkonen P et al (2002) Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 99:12617–12621. https://doi.org/10.1073/pnas.152463399 · DOI
  6. Alberici L, Roth L, Sugahara KN et al (2013) De novo design of a tumor-penetrating peptide. Cancer Res 73:804–812. https://doi.org/10.1158/0008-5472.CAN-12-1668 · DOI
  7. Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:219–227. https://doi.org/10.1016/S1535-6108(02)00051-X · DOI
  8. Arap W (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380. https://doi.org/10.1126/science.279.5349.377 · DOI
  9. Bagri A, Tessier-Lavigne M, Watts RJ (2009) Neuropilins in tumor biology. Clin Cancer Res 15:1860–1864. https://doi.org/10.1158/1078-0432.CCR-08-0563 · DOI
  10. Bastian SEP, Walton PE, Ballard FJ, Belford DA (1999) Transport of IGF-I across epithelial cell monolayers. J Endocrinol 162:361–369. https://doi.org/10.1677/joe.0.1620361 · DOI
  11. Bernkop-Schnurch A (1998) The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 52:1–16. https://doi.org/10.1016/S0168-3659(97)00204-6 · DOI
  12. Bertrand Y, Currie J-C, Poirier J et al (2011) Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer 105:1697–1707. https://doi.org/10.1038/bjc.2011.427 · DOI · Paper page
  13. Bi Y, Liu L, Lu Y et al (2016) T7 Peptide-functionalized PEG-PLGA micelles loaded with carmustine for targeting therapy of glioma. ACS Appl Mater Interfaces 8:27465–27473. https://doi.org/10.1021/acsami.6b05572 · DOI
  14. Boegh M, García-Díaz M, Müllertz A, Nielsen HM (2015) Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation. Eur J Pharm Biopharm 95:136–143. https://doi.org/10.1016/j.ejpb.2015.01.014 · DOI
  15. Boohaker RJ, Lee MW, Vishnubhotla P et al (2012) The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 19:3794–3804. https://doi.org/10.2174/092986712801661004 · DOI
  16. Camenisch G, Alsenz J, Van De Waterbeemd H, Folkers G (1998) Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs lipophilicity and molecular weight. Eur J Pharm Sci 6:313–319. https://doi.org/10.1016/S0928-0987(97)10019-7 · DOI
  17. Ceramide E, Erdreich-epstein A, Shimada H et al (2000) Integrins αvβ3 and αvβ5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased. Cancer Res 60:712–721
  18. Chen C, Duan Z, Yuan Y et al (2017) Peptide-22 and cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB. ACS Appl Mater Interfaces 9:5864–5873. https://doi.org/10.1021/acsami.6b15831 · DOI
  19. Connor Y, Tekleab S, Nandakumar S et al (2015) Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype. Nat Commun 6:8671. https://doi.org/10.1038/ncomms9671 · DOI
  20. Cui Y, Zhang M, Zeng F et al (2016) Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Appl Mater Interfaces 8:32159–32169. https://doi.org/10.1021/acsami.6b10175 · DOI
  21. Cun X, Chen J, Ruan S et al (2015) A novel strategy through combining irgd peptide with tumor-microenvironment-responsive and multistage nanoparticles for deep tumor penetration. ACS Appl Mater Interfaces 7:27458–27466. https://doi.org/10.1021/acsami.5b09391 · DOI
  22. Curnis F, Gasparri A, Sacchi A et al (2004) Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 64:565–571. https://doi.org/10.1158/0008-5472.Can-03-1753 doi · DOI
  23. Curnis F, Sacchi A, Gasparri A et al (2008) Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res 68:7073–7082. https://doi.org/10.1158/0008-5472.CAN-08-1272 · DOI
  24. Dai W, Fan Y, Zhang H et al (2014) A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Drug Deliv 7544:1–11. https://doi.org/10.3109/10717544.2014.903580 · DOI
  25. De G, Ko J-K, Tan T et al (2014) Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment. Oncotarget 5:7734–7747. https://doi.org/10.18632/oncotarget.2301 · DOI
  26. Demeule M, Régina A, Ché C et al (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324:1064–1072. https://doi.org/10.1124/jpet.107.131318 · DOI
  27. Díaz-Perlas C, Sánchez-Navarro M, Teixidó M, Giralt E (2016) Phage display as a tool to discover BBB-shuttle peptides: panning against a human blood-brain barrier cellular model. J Pept Sci 22:S107. https://doi.org/10.1002/bip.22928 · DOI
  28. Du R, Zhong T, Zhang WQ et al (2014) Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma. Int J Nanomed 9:3091–3105. https://doi.org/10.2147/IJN.S65664 · DOI
  29. Duerr DM, White SJ, Schluesener HJ (2004) Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J Virol Methods 116:177–180. https://doi.org/10.1016/j.jviromet.2003.11.012 · DOI
  30. Fan X, Venegas R, Fey R et al (2007) An in vivo approach to structure activity relationship analysis of peptide ligands. Pharm Res 24:868–879. https://doi.org/10.1007/s11095-007-9238-z · DOI
  31. Fievez V, Plapied L, Plaideau C et al (2010) In vitro identification of targeting-ligands of human M cells by phage display. Int J Pharm 394:35–42. https://doi.org/10.1016/j.ijpharm.2010.04.023 · DOI
  32. Fittipaldi A, Giacca M (2005) Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 57:597–608. https://doi.org/10.1016/j.addr.2004.10.011 · DOI
  33. Fogal V, Zhang L, Krajewski S, Ruoslahti E (2008) Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68:7210–7218. https://doi.org/10.1158/0008-5472.CAN-07-6752 · DOI
  34. Frey A, Giannasca KT, Weltzin R et al (1996) Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 184:1045–1059. https://doi.org/10.1084/jem.184.3.1045 · DOI · Paper page
  35. Gaillard PJ, Appeldoorn CCM, Dorland R et al (2014) Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS ONE. https://doi.org/10.1371/journal.pone.0082331 · DOI
  36. Gao H, Qian J, Cao S et al (2012) Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33:5115–5123. https://doi.org/10.1016/j.biomaterials.2012.03.058 · DOI
  37. Gao H, Yang Z, Zhang S et al (2014) Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Acta Biomater 10:858–867. https://doi.org/10.1016/j.actbio.2013.11.003 · DOI
  38. Georgieva JV, Brinkhuis RP, Stojanov K et al (2012) Peptide-mediated blood-brain barrier transport of polymersomes. Angew Chem Int Ed 51:8339–8342. https://doi.org/10.1002/anie.201202001 · DOI
  39. Goldberg M, Gomez-Orellana I (2003) Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2:289–295. https://doi.org/10.1038/nrd1067 · DOI
  40. Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55:1179–1188. https://doi.org/10.1016/0092-8674(88)90262-0 · DOI
  41. Gu G, Gao X, Hu Q et al (2013) The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials 34:5138–5148. https://doi.org/10.1016/j.biomaterials.2013.03.036 · DOI
  42. Guixer B, Arroyo X, Belda I et al (2016) Chemically synthesized peptide libraries as a new source of BBB shuttles. Use of mass spectrometry for peptide identification. J Pept Sci 22:577–591. https://doi.org/10.1002/psc.2900 · DOI
  43. Hambley TW WNH (2009) Is anticancer drug development heading in the right direction?. Cancer Res 69:1259–1262. https://doi.org/10.1158/0008-5472.CAN-08-3786 · DOI
  44. Hamzeh-Mivehroud M, Mahmoudpour A, Rezazadeh H, Dastmalchi S (2008) Non-specific translocation of peptide-displaying bacteriophage particles across the gastrointestinal barrier. Eur J Pharm Biopharm 70:577–581. https://doi.org/10.1016/j.ejpb.2008.06.005 · DOI
  45. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms review of the angiogenic switchduring tumorigenesis. Cell 86:353–364. https://doi.org/10.1016/S0092-8674(00)80108-7 · DOI · Paper page
  46. Higgins LM, Lambkin I, Donnelly G et al (2004) In vivo phage display to identify M cell-targeting ligands. Pharm Res 21:695–705. https://doi.org/10.1023/B:PHAM.0000022418.80506.9a · DOI
  47. Hu Gu G, Liu Z, Jiang M, Kang T, Miao D, Tu Y, Pang Z, Song Q, Yao L, Xia H, Chen H, Jiang X, Gaob X, Chen JQ (2013) F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyP-1 peptide for anti-glioma drug delivery. Biomaterials 34:1135–1145. https://doi.org/10.1016/j.biomaterials.2012.10.048 · DOI
  48. Hwang SR, Byun Y (2014) Advances in oral macromolecular drug delivery. Expert Opin Drug Deliv 11:1955–1967. https://doi.org/10.1517/17425247.2014.945420 · DOI
  49. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48:2641–2658. https://doi.org/10.1146/annurev.bioeng.1.1.241 · DOI
  50. Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241–263. https://doi.org/10.1146/annurev.bioeng.1.1.241 · DOI
  51. Jain RK, Joshi R, Byrav DP et al (2001) Delivery of molecular and cellular medicine to solid tumors1PII of original article: S0169–409X(97)00027 – 6. The article was originally published. Advanced Drug Delivery Reviews 26 (1997) 71–90.1. Adv Drug Deliv Rev 46:149–168. https://doi.org/10.1016/S0169-409X(00)00131-9 · DOI
  52. Järver P, Mäger I, Langel Ü (2010) In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol Sci 31:528–535. https://doi.org/10.1016/j.tips.2010.07.006 · DOI
  53. Jiang T, Olson ES, Nguyen QT et al (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101:17867–17872. https://doi.org/10.1073/pnas.0408191101 · DOI
  54. Jin Y, Song Y, Zhu X et al (2012) Biomaterials Goblet cell-targeting nanoparticles for oral insulin delivery and the in fl uence of mucus on insulin transport. Biomaterials 33:1573–1582. https://doi.org/10.1016/j.biomaterials.2011.10.075 · DOI · Paper page
  55. Kamei N, Morishita M, Eda Y et al (2008a) Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 132:21–25. https://doi.org/10.1016/j.jconrel.2008.08.001 · DOI
  56. Kamei N, Morishita M, Ehara J, Takayama K (2008b) Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery. J Control Release 131:94–99. https://doi.org/10.1016/j.jconrel.2008.07.016 · DOI
  57. Kamei N, Morishita M, Takayama K (2009) Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J Control Release 136:179–186. https://doi.org/10.1016/j.jconrel.2009.02.015 · DOI
  58. Kang SK, Woo JH, Kim MK et al (2008) Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J Biotechnol 135:210–216. https://doi.org/10.1016/j.jbiotec.2008.01.021 · DOI
  59. Kang T, Jiang M, Jiang D et al (2015) Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm 12:2947–2961. https://doi.org/10.1021/acs.molpharmaceut.5b00222 · DOI
  60. Kannan R, Chakrabarti R, Tang D et al (2000) GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res 852:374–382. https://doi.org/10.1016/S0006-8993(99)02184-8 · DOI
  61. Karmali PP, Kotamraju VR, Kastantin M et al (2009) Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine Nanotechnology Biol Med 5:73–82. https://doi.org/10.1016/j.nano.2008.07.007 · DOI
  62. Kauffman B, Fuselier T, He J, Wimley W (2015) Mechanism matters: a taxonomy of cell penetrating peptides. Trends Biochem Sci 40:749–764. https://doi.org/10.3109/10253890.2015.1094689.Post-Traumatic · DOI
  63. Kenngott EE, Cole S, Hein WR et al (2016) Identification of targeting peptides for mucosal delivery in sheep and mice. Mol Pharm 13:202–210. https://doi.org/10.1021/acs.molpharmaceut.5b00635 · DOI
  64. Khafagy ES, Morishita M (2012) Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 64:531–539. https://doi.org/10.1016/j.addr.2011.12.014 · DOI
  65. Kinsella JM, Jimenez RE, Karmali PP et al (2011) X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew Chem Int Ed 50:12308–12311. https://doi.org/10.1002/anie.201104507 · DOI
  66. Koivunen E, Wang B, Ruoslahti E (1995) Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology 13:265–270. https://doi.org/10.1038/nbt0395-265 · DOI
  67. Komin A, Russell LM, Hristova KA, Searson PC (2017) Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: mechanisms and challenges. Adv Drug Deliv Rev 110–111:52–64. https://doi.org/10.1016/j.addr.2016.06.002 · DOI
  68. Kompella UB, Lee VHL (2001) Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev 46:211–245. https://doi.org/10.1016/S0169-409X(00)00137-X · DOI
  69. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E (2002) A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8:751–755. https://doi.org/10.1038/nm720 · DOI
  70. Langguth P, Bohner V, Heizmann J et al (1997) The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release 46:39–57. https://doi.org/10.1016/S0168-3659(96)01586-6 · DOI
  71. Larhed AW, Artursson P, Gråsjö J, Björk E (1997) Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci 86:660–665. https://doi.org/10.1021/js960503w · DOI
  72. Larhed AW, Artursson P, Björk E (1998) The influence of intestinal mucus components on the diffusion of drugs. Pharm Res 15:66–71. https://doi.org/10.1023/A:1011948703571 · DOI
  73. Lee VHL, Yamamoto A (1989) Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev 4:171–207. https://doi.org/10.1016/0169-409X(89)90018-5 · DOI
  74. Lee JH, Engler JA, Collawn JF, Moore BA (2001) Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 268:2004–2012. https://doi.org/10.1046/j.1432-1327.2001.02073.x · DOI
  75. Li J, Feng L, Fan L et al (2011) Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32:4943–4950. https://doi.org/10.1016/j.biomaterials.2011.03.031 · DOI
  76. Li J, Zhang Q, Pang Z et al (2012) Identification of peptide sequences that target to the brain using in vivo phage display. Amino Acids 42:2373–2381. https://doi.org/10.1007/s00726-011-0979-y · DOI
  77. Li J, Zhang C, Li J et al (2013) Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides. Pharm Res 30:1813–1823. https://doi.org/10.1007/s11095-013-1025-4 · DOI
  78. Li M, Tang Z, Zhang D et al (2015a) Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models. Biomaterials 51:161–172. https://doi.org/10.1016/j.biomaterials.2015.02.002 · DOI
  79. Li X, Wang C, Liang R et al (2015b) The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles. Pharm Res 32:1017–1027. https://doi.org/10.1007/s11095-014-1513-1 · DOI
  80. Li Y, Zheng X, Gong M, Zhang J (2016) Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. https://doi.org/10.18632/oncotarget.12708 · DOI
  81. Liang JF, Yang VC (2005) Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 335:734–738. https://doi.org/10.1016/j.bbrc.2005.07.142 · DOI
  82. Lindqvist A, Rip J, Van Kregten J et al (2016) In vivo functional evaluation of increased brain delivery of the opioid peptide DAMGO by glutathione-PEGylated liposomes. Pharm Res 33:177–185. https://doi.org/10.1007/s11095-015-1774-3 · DOI
  83. Lindsay MA (2002) Peptide-mediated cell delivery: application in protein target validation. Curr Opin Pharmacol 2:587–594. https://doi.org/10.1016/S1471-4892(02)00199-6 · DOI
  84. Liu GW, Livesay BR, Kacherovsky NA et al (2015) Efficient identification of murine M2 macrophage peptide targeting ligands by phage display and next-generation sequencing. Bioconjug Chem 26:1811–1817. https://doi.org/10.1021/acs.bioconjchem.5b00344 · DOI
  85. Lundquist P, Artursson P (2016) Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues. Adv Drug Deliv Rev 106:256–276. https://doi.org/10.1016/j.addr.2016.07.007 · DOI
  86. Ma H, Yu P, Shen S, Xu B (2014) A dual functional fluorescent probe for glioma imaging mediated by BBB penetration and glioma cell targeting. Biochem Biophys Res Commun 449:44–48. https://doi.org/10.1016/j.bbrc.2014.04.148 · DOI
  87. Mahmood A, Prüfert F, Efiana NA et al (2016) Cell-penetrating self-nanoemulsifying drug delivery systems (SNEDDS) for oral gene delivery. Expert Opin Drug Deliv 13:1503–1512. https://doi.org/10.1080/17425247.2016.1213236 · DOI
  88. Malcor JD, Payrot N, David M et al (2012) Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting. J Med Chem. https://doi.org/10.1021/jm2014919 · DOI
  89. Matochko WL, Derda R (2015) Next-generation sequencing of phage-displayed peptide libraries. Methods Mol Biol 1248:249–266. https://doi.org/10.1007/978-1-4939-2020-4_17 · DOI
  90. Maussang D, Rip J, van Kregten J et al (2016) Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo. Drug Discov Today Technol 20:59–69. https://doi.org/10.1016/j.ddtec.2016.09.003 · DOI
  91. Mohamadzadeh M, Duong T, Sandwick SJ et al (2009) Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc Natl Acad Sci 106:4331–4336. https://doi.org/10.1073/pnas.0900029106 · DOI
  92. Morishita M, Morishita I, Takayama K et al (1993) Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol Pharm Bull 16:68–72. https://doi.org/10.1248/bpb.16.68 · DOI
  93. Morishita M, Kamei N, Ehara J et al (2007) A novel approach using functional peptides for efficient intestinal absorption of insulin. J Control Release 118:177–184. https://doi.org/10.1016/j.jconrel.2006.12.022 · DOI
  94. Moroz E, Matoori S, Leroux JC (2016) Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv Drug Deliv Rev 101:108–121. https://doi.org/10.1016/j.addr.2016.01.010 · DOI
  95. Murphy EA, Majeti BK, Barnes LA et al (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105:9343–9348. https://doi.org/10.1073/pnas.0803728105 · DOI
  96. Nakase I, Niwa M, Takeuchi T et al (2004) Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol Ther 10:1011–1022. https://doi.org/10.1016/j.ymthe.2004.08.010 · DOI
  97. Nguyen J, Hossain SS, Cooke JRN et al (2017) Flow arrest intra-arterial delivery of small TAT-decorated and neutral micelles to gliomas. J Neurooncol 133:1–9. https://doi.org/10.1007/s11060-017-2429-5 · DOI
  98. Nielsen EJB, Yoshida S, Kamei N et al (2014) In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J Control Release 189:19–24. https://doi.org/10.1016/j.jconrel.2014.06.022 · DOI
  99. Nielsen DS, Shepherd NE, Xu W et al (2017) Orally absorbed cyclic peptides. Chem Rev 117:8094–8128. https://doi.org/10.1021/acs.chemrev.6b00838 · DOI
  100. O’Neill MJ, Bourre L, Melgar S, O’Driscoll CM (2011) Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov Today 16:203–218. https://doi.org/10.1016/j.drudis.2011.01.003 · DOI
  101. O’Sullivan CC, Lindenberg M, Bryla C et al (2016) ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment. Breast Cancer Res Treat 160:51–59. https://doi.org/10.1007/s10549-016-3972-z · DOI
  102. Olive KP, Jacobetz MA, Davidson CJ et al (2009) Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457–1461. https://doi.org/10.1126/science.1171362 · DOI · Paper page
  103. Paasonen L, Sharma S, Braun GB et al (2016) New p32/gC1qR ligands for targeted tumor drug delivery. ChemBioChem 17:570–575. https://doi.org/10.1002/cbic.201500564 · DOI
  104. Pang H-B, Braun GB, Friman T et al (2014) An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat Commun 5:4904. https://doi.org/10.1038/ncomms5904 · DOI
  105. Pardridge WM (2006) Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 6:494–500 · DOI
  106. Pardridge WM (2012) Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab 32:1959–1972. https://doi.org/10.1038/jcbfm.2012.126 · DOI · Paper page
  107. Pasqualini R, Ruoslahti E (1996) Organ targeting In vivo using phage display peptide libraries. Nature 380:364–366. https://doi.org/10.1038/380364a0 · DOI
  108. Pasqualini R, Koivunen E, Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15:542–546. https://doi.org/10.1038/nm0798-822 · DOI
  109. Pasqualini R, Koivunen E, Kain R et al (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722–727
  110. Pauletti GM, Gangwar S, Knipp GT et al (1996) Structural requirements for intestinal absorption of peptide drugs. J Control Release 41:3–17. https://doi.org/10.1016/0168-3659(96)01352-1 · DOI
  111. Pelaseyed T, Bergström JH, Gustafsson JK et al (2014) The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev 260:8–20. https://doi.org/10.1111/imr.12182 · DOI · Paper page
  112. Peterson LW, Artis D (2014) Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 14:141–153. https://doi.org/10.1038/nri3608 · DOI
  113. Pierschbacher MD, Ruoslahti E (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309:30–33. https://doi.org/10.1038/309030a0 · DOI
  114. Porkka K, Laakkonen P, Hoffman JA et al (2002) A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 99:7444–7449. https://doi.org/10.1073/pnas.062189599 · DOI
  115. Prados MD, Schold SC Jr, Fine HA et al (2003) A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol 5:96–103. https://doi.org/10.1215/S1522851702000340 · DOI
  116. Puig-Saus C, Rojas L, Laborda E et al (2014) iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther 21:767–774. https://doi.org/10.1038/gt.2014.52 · DOI
  117. Qosa H, Mohamed LA, Alqahtani S et al (2016) Transporters as drug targets in neurological diseases. Clin Pharmacol Ther 100:441–453. https://doi.org/10.1002/cpt.435 · DOI
  118. Regina A, Demeule M, Tripathy S et al (2015) ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther 14:129–140. https://doi.org/10.1158/1535-7163.MCT-14-0399 · DOI · Paper page
  119. Régina A, Demeule M, Ché C et al (2008) Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155:185–197. https://doi.org/10.1038/bjp.2008.260 · DOI
  120. Ren Y, Cheung HW, von Maltzhan G et al (2012) Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 4:147ra112–147ra112. https://doi.org/10.1126/scitranslmed.3003778 · DOI
  121. Richard JP, Melikov K, Vives E et al (2003) Cell-penetrating peptides: a reevaluation of the mechanism of cellular uptake. J Biol Chem 278:585–590. https://doi.org/10.1074/jbc.M209548200 · DOI
  122. Roth L, Agemy L, Kotamraju VR et al (2012) Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 31:3754–3763. https://doi.org/10.1038/onc.2011.537 · DOI
  123. Rotman M, Welling MM, Bunschoten A et al (2015) Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer’s disease. J Control Release 203:40–50. https://doi.org/10.1016/j.jconrel.2015.02.012 · DOI
  124. Rousselle C, Clair P, Temsamani J, Scherrmann JM(2002).Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J Drug Target. 10(4):309–315 · DOI
  125. Rubas W, Cromwell MEM, Shahrokh Z et al (1996) Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 85:165–169. https://doi.org/10.1021/js950267+ · DOI
  126. Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83–90. https://doi.org/10.1038/nrc724 · DOI
  127. Ruoslahti E (2003) The RGD story: a personal account. Matrix Biol 22:459–465. https://doi.org/10.1016/S0945-053X(03)00083-0 · DOI
  128. Ruoslahti E (2012) Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 24:3747–3756. https://doi.org/10.1002/adma.201200454 · DOI
  129. Ruoslahti E (2017) Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev 110–111:3–12. https://doi.org/10.1016/j.addr.2016.03.008 · DOI
  130. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188:759–768. https://doi.org/10.1083/jcb.200910104 · DOI
  131. Sánchez-Navarro M, Teixidó M, Giralt E (2017) Jumping hurdles: peptides able to overcome biological barriers. Acc Chem Res. https://doi.org/10.1021/acs.accounts.7b00204 · DOI
  132. Sato AK, Viswanathan M, Kent RB, Wood CR (2006) Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17:638–642 · DOI
  133. Schmithals C, Köberle V, Korkusuz H et al (2015) Improving drug penetrability with iRGD leverages the therapeutic response to sorafenib and doxorubicin in hepatocellular carcinoma. Cancer Res 75:3147–3154. https://doi.org/10.1158/0008-5472.CAN-15-0395 · DOI
  134. Schwarze SR (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–1573. https://doi.org/10.1126/science.285.5433.1569 · DOI
  135. Scott Swenson E, Curatolo WJ (1992) (C) Means to enhance penetration. (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv Drug Deliv Rev 8:39–92 · DOI
  136. Sha H, Zou Z, Xin K et al (2015) Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release 200:188–200. https://doi.org/10.1016/j.jconrel.2014.12.039 · DOI
  137. Shah RB, Ahsan F, Khan MA (2002) Oral delivery of proteins: progress and prognostication. Crit Rev Ther Drug Carrier Syst 19:135–169. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v19.i2.20 · DOI
  138. Shen J, Meng Q, Sui H et al (2014) IRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance. Mol Pharm 11:2579–2591. https://doi.org/10.1021/mp400576f · DOI
  139. Shi Y, Jiang X, Zhang L et al (2017) Endothelium-targeted overexpression of heat shock protein 27 ameliorates blood-brain barrier disruption after ischemic brain injury. Proc Natl Acad Sci USA 114(7), E1243–E1252 https://doi.org/10.1073/pnas.1621174114 · DOI
  140. Smith MW, Al-Jayyoussi G, Gumbleton M (2012) Peptide sequences mediating tropism to intact blood-brain barrier: an in vivo biodistribution study using phage display. Peptides 38:172–180. https://doi.org/10.1016/j.peptides.2012.06.019 · DOI
  141. Staquicini FI, Ozawa MG, Moya CA et al (2011) Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest 121:161–173. https://doi.org/10.1172/JCI44798 · DOI
  142. Sugahara KN, Teesalu T, Karmali PP et al (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510–520. https://doi.org/10.1016/j.ccr.2009.10.013 · DOI
  143. Sugahara KN, Teesalu T, Karmali PP et al (2010) Coadministration of a tumor-penetrating peptdei enhances the efficacy of cancer drugs. Science 328:1031–1038. https://doi.org/10.1007/s13398-014-0173-7.2 · DOI
  144. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci 106:16157–16162. https://doi.org/10.1073/pnas.0908201106 · DOI · Paper page
  145. Teesalu T, Sugahara KN, Ruoslahti E (2013) Tumor-penetrating peptides. Front Oncol. https://doi.org/10.3389/fonc.2013.00216 · DOI
  146. Teixidó M, Belda I, Zurita E et al (2005) Evolutionary combinatorial chemistry, a novel tool for SAR studies on peptide transport across the blood-brain barrier. Part 2. Design, synthesis and evaluation of a first generation of peptides. J Pept Sci 11:789–804. https://doi.org/10.1002/psc.679 · DOI
  147. Tian Y, Li S, Song J et al (2014) A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35:2383–2390. https://doi.org/10.1016/j.biomaterials.2013.11.083 · DOI
  148. Toome K, Willmore AM, Paiste P et al (2017) Ratiometric in vivo auditioning of targeted silver nanoparticles. Nanoscale. https://doi.org/10.1039/C7NR04056C · DOI
  149. Tozaki H, Odoriba T, Iseki T et al (1998) Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. J Pharm Pharmacol 50:913–920 · DOI
  150. Tremmel R, Uhl P, Helm F, Wupperfeld D et al (2016) Delivery of copper-chelating trientine (TETA) to the central nervous system by surface modified liposomes. Int J Pharm 512(1):87–95 · DOI
  151. Tuma PL, Hubbard AL (2003) Transcytosis: crossing cellular barriers. Physiol Rev 83:871–932. https://doi.org/10.1152/physrev.00001.2003 · DOI · Paper page
  152. Tyagi M, Rusnati M, Presta M, Giacca M (2001) Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276:3254–3261. https://doi.org/10.1074/jbc.M006701200 · DOI
  153. Urich E, Schmucki R, Ruderisch N et al (2015) Cargo delivery into the brain by in vivo identified transport peptides. Sci Rep 5:14104. https://doi.org/10.1038/srep14104 · DOI
  154. Van Rooy I, Cakir-Tascioglu S, Couraud PO et al (2010) Identification of peptide ligands for targeting to the blood-brain barrier. Pharm Res 27:673–682. https://doi.org/10.1007/s11095-010-0053-6 · DOI
  155. Van Rooy I, Hennink WE, Storm G et al (2012) Attaching the phage display-selected GLA peptide to liposomes: factors influencing target binding. Eur J Pharm Sci 45:330–335. https://doi.org/10.1016/j.ejps.2011.11.015 · DOI
  156. Vela Ramirez JE, Sharpe LA, Peppas NA (2017) Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. https://doi.org/10.1016/j.addr.2017.04.008 · DOI
  157. Walter E, Kissel T, Amidon GL (1996) The intestinal peptide carrier: a potential transport system for small peptide derived drugs. Adv Drug Deliv Rev 20:33–58. https://doi.org/10.1016/0169-409X(95)00129-U · DOI
  158. Wang X, Zhen X, Wang J et al (2013) Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles. Biomaterials 34:4667–4679. https://doi.org/10.1016/j.biomaterials.2013.03.008 · DOI
  159. Wang C-FC-F., Sarparanta MP, Mäkilä EM et al (2015a) Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials 48:108–118. https://doi.org/10.1016/j.biomaterials.2015.01.008 · DOI
  160. Wang J, Yadav V, Smart AL et al (2015b) Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm 12:966–973. https://doi.org/10.1021/mp500809f · DOI
  161. Wang L, Hao Y, Li H et al (2015c) Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles. J Drug Target 2330:1–15. https://doi.org/10.3109/1061186X.2015.1025077 · DOI
  162. Wang Z, Zhao Y, Jiang Y et al (2015d) Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep 5:12651. https://doi.org/10.1038/srep12651 · DOI
  163. Wang N, Jin X, Guo D et al (2017) Iron chelation nanoparticles with delayed saturation as an effective therapy for parkinson disease. Biomacromol 18:461–474. https://doi.org/10.1021/acs.biomac.6b01547 · DOI
  164. Wängler C, Nada D, Höfner G et al (2011) In vitro and initial in vivo evaluation of 68 Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells. Mol Imaging Biol 13:332–341. https://doi.org/10.1007/s11307-010-0329-6 · DOI
  165. Wickham TJ (2000) Targeting adenovirus. Gene Ther 7:110–114. https://doi.org/10.1038/sj.gt.3301115 · DOI
  166. Winer I, Wang S, Lee YEK et al (2010) F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res 70:8674–8683. https://doi.org/10.1158/0008-5472.CAN-10-1917 · DOI
  167. Woodley JF (1994) Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 11:61–95
  168. Wu Y, Luo X, Liu X et al (2015) Intraperitoneal administration of a Novel TAT-BDNF peptide ameliorates cognitive impairments via modulating multiple pathways in two alzheimer’s rodent models. Sci Rep 5:15032. https://doi.org/10.1038/srep15032 · DOI
  169. Xia H, Anderson B, Mao Q, Davidson BL (2000) Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 74:11359–11366. https://doi.org/10.1128/jvi.74.23.11359-11366.2000 · DOI
  170. Yamaguchi S, Ito S, Kurogi-Hirayama M, Ohtsuki S (2017) Identification of cyclic peptides for facilitation of transcellular transport of phages across intestinal epithelium in vitro and in vivo. J Control Release 262:232–238. https://doi.org/10.1016/j.jconrel.2017.07.037 · DOI
  171. Yan C, Gu J, Hou D et al (2015) Improved tumor targetability of Tat-conjugated PAMAM dendrimers as a novel nanosized anti-tumor drug carrier. Drug Dev Ind Pharm 41:617–622. https://doi.org/10.3109/03639045.2014.891127 · DOI
  172. Yan F, Wu H, Liu H et al (2016) Molecular imaging-guided photothermal/photodynamic therapy against tumor by iRGD-modified indocyanine green nanoparticles. J Control Release 224:217–228. https://doi.org/10.1016/j.jconrel.2015.12.050 · DOI
  173. Yao VJ, D’Angelo S, Butler KS et al (2016) Ligand-targeted theranostic nanomedicines against cancer. J Control Release 240:267–286. https://doi.org/10.1016/j.jconrel.2016.01.002 · DOI
  174. Yoo MK, Kang SK, Choi JH et al (2010) Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique. Biomaterials 31:7738–7747. https://doi.org/10.1016/j.biomaterials.2010.06.059 · DOI
  175. Yu KF, Zhang WQ, Luo LM et al (2013) The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomed 8:2473–2485. https://doi.org/10.2147/IJN.S46962 · DOI
  176. Yun Y, Cho YW, Park K (2013) Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev 65:822–832. https://doi.org/10.1016/j.addr.2012.10.007 · DOI
  177. Zhang L, Song L, Zhang C, Ren Y (2012) Improving intestinal insulin absorption efficiency through coadministration of cell-penetrating peptide and hydroxypropyl-β-cyclodextrin. Carbohydr Polym 87:1822–1827. https://doi.org/10.1016/j.carbpol.2011.10.002 · DOI
  178. Zhang B, Sun X, Mei H et al (2013a) LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials 34:9171–9182. https://doi.org/10.1016/j.biomaterials.2013.08.039 · DOI
  179. Zhang C, Wan X, Zheng X et al (2013b) Biomaterials dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’ s disease mice. Biomaterials 35:1–10. https://doi.org/10.1016/j.biomaterials.2013.09.063 · DOI
  180. Zhang C, Zheng X, Wan X et al (2014) The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer’s disease. J Control Release 192:317–324. https://doi.org/10.1016/j.jconrel.2014.07.050 · DOI
  181. Zhang Q, Zhang Y, Li K et al (2015) A novel strategy to improve the therapeutic efficacy of Gemcitabine for non-small cell lung cancer by the tumor-penetrating peptide iRGD. PLoS ONE. https://doi.org/10.1371/journal.pone.0129865 · DOI
  182. Zhang Y, Zhai M, Chen Z et al (2017) Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv 24:1045–1055. https://doi.org/10.1080/10717544.2017.1344334 · DOI
  183. Zhu Z, Xie C, Liu Q et al (2011) The effect of hydrophilic chain length and iRGD on drug delivery from poly(ε-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles. Biomaterials 32:9525–9535. https://doi.org/10.1016/j.biomaterials.2011.08.072 · DOI
  184. Zhu S, Chen S, Gao Y et al (2015) Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and engrailed secretion peptide (Sec). Drug Deliv 0:1–12. https://doi.org/10.3109/10717544.2015.1043472 · DOI
  185. Zong T, Mei L, Gao H et al (2014) Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm 11:2346–2357. https://doi.org/10.1021/mp500057n · DOI
  186. Zupančič O, Bernkop-Schnürch A (2017) Lipophilic peptide character—what oral barriers fear the most. J Control Release 255:242–257. https://doi.org/10.1016/j.jconrel.2017.04.038 · DOI
  187. Zuris JA, Thompson DB, Shu Y et al (2014) Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33:73–80. https://doi.org/10.1038/nbt.3081 · DOI · Paper page

Cited by

Sorted by citations

See all 102

Metadata

Authors
Ghosh, D., Peng, X., Leal, J., & Mohanty, R. P.
Venue
Journal of Pharmaceutical Investigation
Publisher
Springer Science and Business Media LLC
Published
2017-12-12
Volume
48
Issue
1
Pages
89-111
ISSN
  • 2093-5552
  • 2093-6214
DOI
10.1007/s40005-017-0374-0
PMC
PMC6023411
Cited by
102
References
6
Language
en
Licence
Funders
National Heart, Lung, and Blood Institute (R01 HL138251-01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review